pharmaphorum

JANUARY 5, 2022

The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR inhibitors. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on.

FDA 111

FDA Chemotherapy 111

pharmaphorum

JANUARY 5, 2021

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Immunization 52

Immunization Vaccines 52

pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Labelling 52

Labelling Chemotherapy Immunization 52

pharmaphorum

OCTOBER 29, 2021

Gilead’s Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan) will be paired with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in a new phase 3 trial in previously-untreated subjects with locally advanced or metastatic TNBC. While its headline revenue of $7.4

Chemotherapy 52

Chemotherapy FDA 52

European Pharmaceutical Review

DECEMBER 27, 2023

This is in addition to its considerable price tag. Car-t “The living drugs”, immune checkpoint inhibitors, and precision medicine: A new era of cancer therapy. The demand for CAR T-cell therapy is therefore much greater than the supply, making it difficult for patients to access the potentially life-saving treatment. 2019;12(1).

Adverse Reactions 85

Adverse Reactions Immunization Medical Schools Chemotherapy 85